Compare prices and buy NAD+ from 47 research peptide vendors - also called suppliers or sources. Updated daily.
beta-Nicotinamide adenine dinucleotide (CAS 53-84-9), a dinucleotide cofactor (not a peptide) central to cellular energy metabolism and the substrate of sirtuin deacetylases, PARPs, and CD38. Tissue NAD+ levels decline with age in rodents and humans, which is the rationale behind research into raising them. Sold by research-peptide vendors as vials and sprays. Oral precursors (NR, NMN) are marketed as supplements but fall outside this catalog. It has no FDA-approved drug application.
For research purposes only. Not medical advice.
NAD+ (beta-nicotinamide adenine dinucleotide) is not a peptide but a dinucleotide coenzyme, catalogued here because research-peptide vendors sell it alongside longevity compounds. It is one of the most fundamental molecules in metabolism: the NAD+/NADH pair shuttles electrons through glycolysis, the citric acid cycle, and oxidative phosphorylation, making NAD+ essential to how cells extract energy from nutrients.
Beyond that redox role, NAD+ is consumed as a substrate by three main enzyme families: the sirtuins (deacetylases tied to metabolic and stress-response signaling), the PARPs (involved in DNA repair), and CD38. Because these enzymes use NAD+ up rather than merely borrowing it, cellular demand is continuous. A well-documented observation is that tissue NAD+ levels tend to decline with age, which is what has made raising NAD+ such a heavily researched, and heavily marketed, idea.
Two oral precursors, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), are sold as dietary supplements and converted by cells into NAD+. PeptideScouter indexes no listings for either. Research-peptide vendors sell NAD+ itself, as vials and sprays. The human evidence splits along the same line, and a precursor result is not a result for NAD+. In a 2018 randomized, placebo-controlled crossover trial in healthy middle-aged and older adults (Martens et al., Nature Communications), oral NR raised NAD+ in blood mononuclear cells by about 60% compared with placebo, measured in participants who completed the trial. For NAD+ itself, a 2019 pilot study of an intravenous infusion (Grant et al., Frontiers in Aging Neuroscience) found no change in plasma NAD+ or its measured metabolites for the first two hours, which the authors read as rapid removal from plasma. Neither study measured NAD+ in solid tissue.
NAD+ is an endogenous coenzyme with no FDA-approved drug application: Drugs@FDA returns no match for nadide or nicotinamide adenine dinucleotide (checked October 21, 2026), and FDA's 503B categories document does not mark it as a component of an approved drug. It does sit inside the compounding nomination process, though not in Category 2. FDA lists NAD in Category 1, substances under evaluation, for both the Section 503A bulks list (categories document updated May 14, 2026) and the Section 503B list (updated March 21, 2025), and under the 503A interim policy FDA does not intend to act against a compounder using a Category 1 substance, provided the policy's conditions are met. A separate nomination of the disodium salt trihydrate sits in Category 3, nominated without adequate support, on both lists.
The precursor NMN took a different route. In November 2022 the FDA concluded that NMN could not be sold as a dietary supplement because it had first been authorized for investigation as a drug. The agency reversed that position on September 29, 2025, concluding that NMN had been marketed as a supplement before that authorization. Research-vendor NAD+ is sold for research use only, not for human consumption.
NAD+ is listed under its own name, often with formulation qualifiers such as "buffered NAD+" or "pH-balanced NAD+". It is sold alongside glutathione, a tripeptide antioxidant, and 5-Amino-1MQ, a small-molecule NNMT inhibitor, and inside the NAD+ + MOTS-C + 5-Amino-1MQ blend, whose per-milligram figure covers all three components and is not comparable to a single-compound vial. PeptideScouter computes a per-milligram price for NAD+ vials and verifies identity against the free-acid molecular formula (C21H27N7O14P2, CAS 53-84-9).
No. NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme, not a peptide. It is catalogued on PeptideScouter for commercial reasons, because research-peptide vendors sell NAD+ vials and sprays alongside their peptide catalogs.
NAD+ is the active coenzyme the body uses. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors that cells convert into NAD+, and are the forms usually sold as oral supplements. PeptideScouter indexes NAD+ itself and no listings for NMN or NR.
No. NAD+ is a naturally occurring coenzyme with no FDA-approved drug application. For compounding, FDA lists it in Category 1, substances under evaluation, for both the Section 503A and Section 503B bulk drug substance lists, and it appears on neither Category 2 safety-risk list. Separately, the FDA excluded the precursor NMN from dietary-supplement status in 2022, then reversed that in September 2025. Research-vendor NAD+ is sold for laboratory use only, not for human consumption.
Not intact, in rat studies. In rats, NAD+ in the small intestine was broken down to nicotinamide mononucleotide and then nicotinamide riboside, and nicotinamide was the main labelled compound absorbed (Gross and Henderson, Journal of Nutrition, 1983). The oral precursors are a different case. In a 2018 randomized, placebo-controlled crossover trial, oral nicotinamide riboside raised NAD+ in blood mononuclear cells by about 60% compared with placebo, measured in participants who completed the trial.
PeptideScouter computes per-milligram pricing for vials, where the listing is a single mass of material. NAD+ sprays, tablets and bulk raw-material listings are indexed with their prices but excluded from per-milligram comparisons, so the per-milligram figures on this page cover vials only.
NAD+ is sold by 47 research peptide vendors indexed on PeptideScouter, with 117 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
45 of the 47 indexed vendors currently have NAD+ in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Studz Peptides currently lists NAD+ at $0.03/mg, the lowest listed price across 47 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $0.03/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. 46 of the 47 vendors listing NAD+ publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $0.03/mg listed to $0.03/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
NAD+ ranges from $0.03/mg to $0.48/mg across 117 listings from 47 research peptide vendors, normalized to USD per milligram and refreshed daily.
47 research peptide vendors currently list NAD+ on PeptideScouter, with 45 in stock right now. We track 117 listings across size and kit variants.
NAD+'s CAS Registry Number is 53-84-9. It is also sold as NAD+ (Nicotinamide Adenine Dinucleotide), NAD+ pH Balanced, NAD+ Buffered.
